Industry Lunch Session

Friday, September 16, 2016

Industry Lunch Session supported by Myriad


Title: myPlan Lung Cancer: A 46 Gene Prognostic Signature In Early Stage NSCLC Adenocarcinoma

Description: An update on clinical information on myPlan Lung Cancer, a commercially available molecular prognostic signature for early stage NSCLC adenocarcinoma. The signature is a clinically reproducible high-risk feature that provides information above and beyond all known clinical, pathological, and surgical high-risk features in predicting risk of death.

Switch To Full Site